The immuno-oncology therapy developer's investors include Pfizer and Gilead Sciences, both of which contributed to a $300m round in January.
US-based cancer drug developer Allogene Therapeutics has filed for a $100m initial public offering that will enable pharmaceutical companies Pfizer and Gilead Sciences to exit.
Allogene is working on genetically engineered allogeneic T cell medicines designed to kill cancer cells. The therapies will be based on cells taken from healthy donors, meaning patients can theoretically be treated more easily and more quickly.
The IPO proceeds will be used to fund clinical trials for the company’s product candidates being developed…
